New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The

Human hookworm, schistosomiasis, Chagas disease and leishmaniasis are some of the most devastating diseases in poverty with no licensed vaccine available.

What do neglected tropical diseases (NTDs) have to do with women’s health? A recent review entitled, “Effective Health Interventions for Adolescents That Could Be Integrated with Human Papillomavirus Vaccination Programs”, has just been published looking at how combining multiple health interventions with human papillomavirus (HPV) vaccinations increases the effectiveness of HPV delivery.

Last week, the High-Level Panel of Eminent Persons on the Post-2015 Development Agenda released a report – A New Global Partnership: Eradicate Poverty and Transform Economics through Sustainable Development.

Pages

Subscribe to RSS - Hookworm